Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2025-03-17 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于控股股东及其一致行动人持股比例变动触及1%整数倍及减持计划期限届满暨实施结果的公告
Major Shareholding Notification Classification · 95% confidence The document is an official announcement from Shenzhen Huada Gene Co., Ltd. regarding the change in shareholding proportions of its controlling shareholder and related parties, specifically about the expiration and implementation results of a share reduction plan. It details the number of shares reduced, the percentage change in shareholding, the method of reduction (block trades), and compliance with relevant securities laws and regulations. The document includes tables showing shareholding before and after the reduction and confirms no violation of laws. It is not a financial report, earnings release, or management discussion but a regulatory announcement about shareholding changes and share reduction plan completion. This fits the definition of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is over 6000 characters, so it is not a mere announcement of a report but a substantive disclosure. Therefore, the correct classification is MRQ with high confidence.
2025-03-17 Chinese
关于控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the controlling shareholder of Shenzhen BGI Genomics Co., Ltd. It details the number of shares pledged, the proportion of total shares, the purpose of the pledge, and the risk assessment related to the pledge. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about a financing-related event (share pledge) by a major shareholder, which fits the category of Capital/Financing Update (CAP). The document length is 2373 characters, which is relatively short but contains substantive information about share pledging, not just a notice or report publication. Therefore, it is not a Report Publication Announcement or Regulatory Filing fallback. Hence, the best classification is CAP with high confidence.
2025-03-03 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二五年第一次临时股东会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of Shenzhen BGI Genomics Co., Ltd.'s 2025 first extraordinary general meeting of shareholders. It details the legal compliance of the meeting's call, attendance, and voting process under relevant Chinese securities and company laws. The document does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of a report but a legal opinion on the shareholder meeting. This type of document is best classified as a Regulatory Filing (RNS) because it is a legal compliance document related to corporate governance and shareholder meetings that does not fit into more specific categories like AGM Information or Declaration of Voting Results, as it is a legal opinion rather than the meeting materials or voting results announcement itself.
2025-02-11 Chinese
2025年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2025 First Extraordinary General Meeting of Shareholders" of Shenzhen BGI Genomics Co., Ltd. It details the meeting date, voting procedures, attendance, and voting results on specific proposals. It includes legal opinions on the meeting's legality and compliance. The content is focused on the announcement of the shareholder meeting resolutions and voting outcomes, not the full meeting materials or presentations. The document length is 2380 characters, which is relatively short and consistent with a formal announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-02-11 Chinese
关于召开2025年第一次临时股东会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the 2025 first extraordinary general meeting (临时股东会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), registration details, agenda items, and proxy voting instructions. It does not contain any financial statements, audit results, or earnings data. The document is not a report itself but a notice or announcement related to a shareholders' meeting. It is not a voting results declaration since it is issued before the meeting date and does not disclose voting outcomes. The document is also not a proxy solicitation statement as it does not solicit votes but informs about the meeting and voting process. Given the content and length (4579 characters), it fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement about the meeting logistics and procedures, which do not fit other more specific categories.
2025-02-06 Chinese
关于股东回馈活动的自愿性信息披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary information disclosure announcement by Shenzhen BGI Genomics Co., Ltd. regarding a shareholder appreciation activity. It details the scope, timing, content, registration method, and other notes about the activity aimed at rewarding shareholders. There is no financial data, no report attached or referenced as being published, and no regulatory certification or voting results. The document is an announcement about a shareholder-related event, specifically a shareholder reward program, which does not fit into categories like Annual Report, Earnings Release, or Proxy Solicitation. It is not a report publication announcement since it does not mention any report release. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-02-05 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.